Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-05-28
2000-07-11
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544118, 544123, 544251, A61K 31505, C07D48704
Patent
active
06087368&
ABSTRACT:
Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.
REFERENCES:
patent: 4352931 (1982-10-01), Cuny et al.
patent: 5116843 (1992-05-01), Mertens et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5346901 (1994-09-01), Bell et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5482941 (1996-01-01), Terrett
Hudlicky, Milos., Reductions in Organic Chemistry, 41-73, 1984.
Drugs of the Future 1997, 22(2): 138-143.
Cushman David W.
Macor John E.
Rotella David P.
Weller, III Harold N.
Yevich Joseph P.
Babajko Suzanne
Balasubramanian V
Bristol--Myers Squibb Company
Davis Stephen B.
Shah Mukund J.
LandOfFree
Quinazolinone inhibitors of cGMP phosphodiesterase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinazolinone inhibitors of cGMP phosphodiesterase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinazolinone inhibitors of cGMP phosphodiesterase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542711